Zentalis PharmaceuticalsL Book Value per Share Over Time
| ZNTL Stock | USD 12.57 0.43 3.31% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Zentalis PharmaceuticalsL Performance and Zentalis PharmaceuticalsL Correlation. Zentalis |
Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.47) | Return On Assets (0.29) | Return On Equity (0.67) |
The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis PharmaceuticalsL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Book Value Per Share Analysis
Compare Zentalis PharmaceuticalsL and related stocks such as Sana Biotechnology, Olema Pharmaceuticals, and Cullinan Oncology LLC Book Value per Share Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SANA | (0.7609) | (0.7609) | (0.7609) | (0.7609) | (0.7609) | (0.7609) | (0.7609) | (0.7609) | (0.7609) | (0.7609) | (2.2462) | 4.3771 | 2.6511 | 1.4779 | 0.88 |
| OLMA | (0.4453) | (0.4453) | (0.4453) | (0.4453) | (0.4453) | (0.4453) | (0.4453) | (0.4453) | (0.4453) | (0.2637) | 8.6022 | 7.1999 | 4.9392 | 5.6113 | 3.42 |
| CGEM | (1.8036) | (1.8036) | (1.8036) | (1.8036) | (1.8036) | (1.8036) | (1.8036) | (1.8036) | (1.8036) | (0.937) | (1.7842) | 9.5407 | 11.8464 | 10.9194 | 11.47 |
| LIFE | (95.1981) | (95.1981) | (95.1981) | (95.1981) | 6.8491 | 102 | 37.1274 | 34.8618 | 15.7258 | 6.2659 | 3.437 | 5.7191 | 2.5083 | 1.6912 | 1.61 |
| GLUE | (0.2761) | (0.2761) | (0.2761) | (0.2761) | (0.2761) | (0.2761) | (0.2761) | (0.2761) | (0.2761) | (0.2761) | (1.1074) | 7.4677 | 5.7469 | 3.4876 | 2.45 |
| DSGN | (0.1339) | (0.1339) | (0.1339) | (0.1339) | (0.1339) | (0.1339) | (0.1339) | (0.1339) | (0.1339) | (0.1339) | (0.2102) | 8.3187 | 5.8755 | 0.005 | 0.0047 |
| ERAS | (0.1144) | (0.1144) | (0.1144) | (0.1144) | (0.1144) | (0.1144) | (0.1144) | (0.1144) | (0.1144) | (0.1144) | (0.9582) | (1.9997) | (3.9416) | 2.1086 | 2.21 |
| DAWN | (0.1723) | (0.1723) | (0.1723) | (0.1723) | (0.1723) | (0.1723) | (0.1723) | (0.1723) | (0.1723) | (0.1723) | (0.8753) | (2.0578) | (4.1192) | 4.3441 | 4.56 |
| INZY | (0.9166) | (0.9166) | (0.9166) | (0.9166) | (0.9166) | (0.9166) | (0.9166) | (0.9166) | (0.9166) | (1.4218) | 6.7607 | 4.6382 | 3.1405 | 2.7099 | 1.99 |
| SNDX | (0.4167) | (0.4167) | (0.4167) | 1.4797 | (0.5956) | 3.8392 | 5.7552 | 4.9682 | 2.0908 | 1.0364 | 6.105 | 7.8435 | 7.6933 | 7.8754 | 8.27 |
| PTGX | 1.3518 | 1.3518 | 1.3518 | 1.3518 | 1.3518 | 1.6306 | (9.9346) | (5.7391) | (6.2811) | (8.4058) | (8.2512) | (8.8371) | (10.9448) | 5.9312 | 6.23 |
| RVMD | 0.1242 | 0.1242 | 0.1242 | 0.1242 | 0.1242 | 0.1242 | 0.1242 | 0.1242 | 2.6501 | 2.5853 | 7.1273 | 8.2763 | 8.4983 | 16.1396 | 16.95 |
| BPMC | (0.1143) | (0.1143) | (0.1143) | (0.1143) | 2.708 | 7.8955 | 7.7506 | 16.5102 | 9.5518 | 9.7087 | 26.9573 | 16.5887 | 8.6294 | 2.1568 | 2.05 |
| KYMR | (1.7099) | (1.7099) | (1.7099) | (1.7099) | (1.7099) | (1.7099) | (1.7099) | (1.7099) | (1.7099) | (1.6709) | 16.3628 | 9.578 | 9.0881 | 6.7672 | 5.12 |
| ITOS | 2.0042 | 2.0042 | 2.0042 | 2.0042 | 2.0042 | 2.0042 | 2.0042 | 2.0042 | 2.0042 | 0.4474 | 9.2224 | 15.7134 | 18.6581 | 16.0842 | 8.28 |
| ANNX | 3.3076 | 3.3076 | 3.3076 | 3.3076 | 3.3076 | 3.3076 | 3.3076 | 3.3076 | 3.3076 | 1.1389 | 20.2965 | 6.0525 | 4.2286 | 3.311 | 3.15 |
Zentalis PharmaceuticalsL and related stocks such as Sana Biotechnology, Olema Pharmaceuticals, and Cullinan Oncology LLC Book Value Per Share description
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.My Equities
My Current Equities and Potential Positions
| Zentalis PharmaceuticalsLlc | ZNTL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 12.57
Check out Zentalis PharmaceuticalsL Performance and Zentalis PharmaceuticalsL Correlation. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Zentalis Stock analysis
When running Zentalis PharmaceuticalsL's price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Zentalis PharmaceuticalsL technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.